Geevan Sagar
Inflammatory diseases, particularly autoimmune disorders such as
rheumatoid arthritis, Crohn’s disease, and ulcerative colitis, are characterized
by persistent, dysregulated inflammation, leading to tissue damage and
a reduction in quality of life. The underlying mechanism in many of these
diseases involves an overactive immune response, where pro-inflammatory
cytokines, such as Tumor Necrosis Factor-Alpha (TNF-α), play a crucial role
in mediating inflammation and disease progression. Infliximab, a monoclonal
antibody against TNF-α, is one of the most widely used biologic therapies for
treating various inflammatory conditions. Since its approval in the late 1990s,
infliximab has revolutionized the management of diseases that are resistant
to traditional therapies, offering patients significant improvements in disease
control, symptom relief, and quality of life.
Share this article
